From Big to Little: Numbers that Matter in Today’s Clinical Research Enterprise

Clinical Researcher—December 2023 (Volume 37, Issue 6)

BY THE NUMBERS

Curated by Gary W. Cramer, Managing Editor for ACRP

$34 billion The approximate amount of revenue generated by the top 10 contract research organizations in 2022, representing an estimated 69% of total revenue spent on contract clinical services globally.

Source: https://www.appliedclinicaltrialsonline.com/view/outsourcing-model-usage-and-its-relationship-to-clinical-trial-performance

$2.2 million The per-patient cost of treatment with a newly U.S. Food and Drug Administration–approved, CRISPR-based therapy for sickle cell disease, the first to use the gene-editing tool.

Source: https://www.nbcnews.com/health/health-news/fda-approves-cure-sickle-cell-disease-first-treatment-use-gene-editing-rcna127979

20,109 The number of drugs in the research and development pipeline in 2022, up from 17,737 in 2020.

Source: https://www.contractpharma.com/issues/2023-06-01/view_features/cro-industry-report/?widget=listSection

6.79 vs. 0 The number of cancer clinical trials per 10,000 individuals run from 2005 to 2023 in the province of New Brunswick, Canada, as opposed to the number run in Canada’s three territories.

Source: https://medicalxpress.com/news/2023-12-reveals-inequities-access-cancer-clinical.html

2% to 14% The rate at which all adolescents and young adults are estimated to participate in clinical trials.

Source: https://breakingcancernews.com/2023/11/28/ayas-in-clinical-trials-underrepresented-and-underserved/

▲▼▲